AI in Healthcare — Systematic Review of Economic Evidence and Cost-Effectiveness
OVERVIEWA systematic review of economic evidence for AI in healthcare, published in a peer-reviewed journal, identified 91 records representing 98 unique economic evaluations. Of these, 36% demonstrated a clear health economic preference for the AI technology, rising to 44% when restricted to the 51 highest-quality studies. AI interventions were most commonly designed for healthcare providers, with ophthalmology and oncology being the most frequent application areas. The review explicitly challenges ambitious projections that AI could save $200–360 billion annually in U.S. healthcare and €212 billion in Europe, finding that current empirical evidence does not yet support these figures. High-quality studies show "definite potential" for positive cost-effectiveness, but the evidence base remains insufficient to validate headline savings claims. When combined with findings from randomized controlled trials of clinical AI, the evidence suggests AI technologies frequently yield improvements in clinical and economic outcomes or match the current standard of care, rather than dramatically exceeding it. A complementary meta-analysis specifically examining AI-assisted diabetic retinopathy (DR) screening found that AI-assisted screening was significantly more cost-effective than human grader-based screening, with a pooled incremental net monetary benefit of $2,179.39 per individual. Compared with no screening, AI-assisted DR screening yielded a pooled INMB of $3,606.10 from a societal…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.